Inventor · disambiguated record
Avery D. Posey
Also filed as: POSEY AVERY · POSEY AVERY D · POSEY JR AVERY D
10 granted patents·11 pending applications·52 citations·filing 2013–2024
87Inventor score
Top patents by PatentIndex Score
21 records- 0196US11090336B2Tn-MUC1 chimeric antigen receptor (CAR) T cell therapyUNIV PENNSYLVANIA·Filed 2020·Granted Aug 17, 2021·5 cites·10 claims
- 0295US9783591B2Use of the CD2 signaling domain in second-generation chimeric antigen receptorsUNIV PENNSYLVANIA·Filed 2013·Granted Oct 10, 2017·33 cites·2 claims
- 0393US11597754B2Use of the CD2 signaling domain in second-generation chimeric antigen receptorsUNIV PENNSYLVANIA·Filed 2019·Granted Mar 7, 2023·4 cites·20 claims
- 0491US12234274B2Use of the CD2 signaling domain in second-generation chimeric antigen receptorsUNIV PENNSYLVANIA·Filed 2021·Granted Feb 25, 2025·1 cites·23 claims
- 0590US10501519B2Use of the CD2 signaling domain in second-generation chimeric antigen receptorsUNIV PENNSYLVANIA·Filed 2017·Granted Dec 10, 2019·6 cites·3 claims
- 0687US11673964B2Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemiasUNIV PENNSYLVANIA·Filed 2019·Granted Jun 13, 2023·2 cites·20 claims
- 0786US12227588B2Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemiasUNIV PENNSYLVANIA·Filed 2024·Granted Feb 18, 2025·0 cites·22 claims
- 0881US2023242612A1Use of the cd2 signaling domain in second-generation chimeric antigen receptorsUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 0979US11535662B2CD28 compositions and methods for chimeric antigen receptor therapyNOVARTIS AG·Filed 2018·Granted Dec 27, 2022·1 cites·12 claims
- 1077US2023331864A1Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and LeukemiasUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 1170US2023052970A1Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1267US2023312677A1Cd28 compositions and methods for chimeric antigen receptor therapyNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1363US2021338733A1Tn-MUC1 Chimeric Antigen Receptor (CAR) T Cell TherapyUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 1460US2021032661A1Methods And Compositions Comprising A Viral Vector For Expression Of A Transgene And An EffectorUNIV PENNSYLVANIA·Filed 2019·Application pending·0 cites
- 1558US12473342B2Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosisUNIV PENNSYLVANIA·Filed 2019·Granted Nov 18, 2025·0 cites·29 claims
- 1655US2024299541A1Selective stimulation of t cells in solid tumors using oncolytic viral delivery of orthogonal il-2UNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 1754US11459390B2Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptorNOVARTIS AG·Filed 2016·Granted Oct 4, 2022·0 cites·21 claims
- 1853US2021230246A1Use of inhibitory chimeric receptors to prevent t cell-induced blood brain barrier damageUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 1950US2020370013A1Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid TumorsUNIV PENNSYLVANIA·Filed 2020·Application pending·0 cites
- 2045US2022380447A1Fibronectin targeting chimeric antigen receptors (cars)UNIV PENNSYLVANIA·Filed 2020·Application pending·0 cites
- 2136US2017209492A1Subset-optimized chimeric antigen receptor-containing t-cellsJUNE CARL H·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →